{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T20:16:38Z","timestamp":1767644198848,"version":"3.48.0"},"reference-count":76,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:p>\n                    <jats:bold>Osteoporosis is under-recognized and undertreated among postmenopausal women. Nitrogen-containing bisphosphonates are its first-line pharmacotherapy. Oral bisphosphonate treatment requires stringent dosing guidelines to minimize gastrointestinal irritation and enhance absorption. This paper reviews the efficacy, safety and tolerability of quarterly intravenous ibandronate 3 mg injection, approved in 2006 in the USA and Europe. Quarterly intravenous ibandronate injection has shown superior efficacy to daily oral ibandronate for bone mineral density increase and fracture prevention. No drug-related serious atrial fibrillation events have been reported with intravenous ibandronate. The regimen has a favorable renal safety profile. Quarterly intravenous ibandronate is administered as a simple 15-s intravenous injection in a physician's office and provides a beneficial option for patients who are unable to tolerate oral administration.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.2217\/17455057.4.3.219","type":"journal-article","created":{"date-parts":[[2009,5,15]],"date-time":"2009-05-15T08:23:09Z","timestamp":1242375789000},"page":"219-228","source":"Crossref","is-referenced-by-count":1,"title":["Quarterly Intravenous Ibandronate for Postmenopausal Osteoporosis"],"prefix":"10.1177","volume":"4","author":[{"given":"Ronald D","family":"Emkey","sequence":"first","affiliation":[{"name":"Emkey Osteoporosis &amp; Arthritis Clinic, 1235 Penn Avenue, Suite 200, Wyomissing, PA 19610, USA, Tel.: +1 610 374 8109; Fax: +1 610 375 1206;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,5]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022 \u2022) to readers."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50455.x"},{"volume-title":"Bone Health and Osteoporosis: a Report of the Surgeon General","year":"2004","key":"e_1_3_2_5_2","unstructured":"Bone Health and Osteoporosis: a Report of the Surgeon General. U.S. Department of Health and Human Services. Office of the Surgeon General, Rockville, MD, USA (2004)."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2005.06.004"},{"key":"e_1_3_2_8_2","volume-title":"Prevention and Management of Osteoporosis","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Prevention and Management of Osteoporosis. World Health Organization, Geneva, Switzerland (2006)."},{"key":"e_1_3_2_9_2","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group","volume":"12","author":"Schnitzer T","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, : Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group. Aging (Milano) 12, 1\u201312 (2000).","journal-title":"Aging (Milano)"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440503"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8"},{"key":"e_1_3_2_12_2","first-page":"S217","article-title":"The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis \u2013 1 year study results","volume":"18","author":"McClung M","year":"2007","unstructured":"McClung M, Benhamou CL, Man Z, : The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis \u2013 1 year study results. Osteoporos. Int. 18, S217 (2007) (Abstract P8.6).","journal-title":"Osteoporos. Int."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044958"},{"key":"e_1_3_2_14_2","unstructured":"Study supporting approval of monthly oral ibandronate.."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730090-00003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2007.06.005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21918"},{"key":"e_1_3_2_18_2","unstructured":"First publication of the study supporting quarterly intravenous (i.v.) ibandronate.."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200310233491721"},{"key":"e_1_3_2_21_2","unstructured":"Evidence for renal safety concerns with i.v. zoledronic acid.."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2217\/17455057.2.3.341"},{"key":"e_1_3_2_23_2","unstructured":"Review of pharmacology pharmacokinetics efficacy and safety of monthly oral and quarterly i.v. ibandronate.."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.1.0325"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623942"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666120-00005"},{"key":"e_1_3_2_27_2","unstructured":"Comprehensive review of i.v. ibandronate pharmacology and pharmacokinetics.."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004267594"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.03.005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0174-3"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.12.020"},{"key":"e_1_3_2_32_2","first-page":"S455","article-title":"Oral monthly ibandronate is associated with rapid suppression of serum CTX within three days of treatment initiation","volume":"22","author":"Silverman SL","year":"2007","unstructured":"Silverman SL, Barrett-Connor E, Simonelli C, Kohles JD, Dasic G, Binkley NC: Oral monthly ibandronate is associated with rapid suppression of serum CTX within three days of treatment initiation. J. Bone Miner. Res. 22(Suppl. 1), S455 (2007) (Abstract W367).","journal-title":"J. Bone Miner. Res."},{"key":"e_1_3_2_33_2","unstructured":"Study demonstrating onset of biomarker suppression within 3 days and nadir within 7 days of ibandronate treatment.."},{"key":"e_1_3_2_34_2","first-page":"853","article-title":"Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate","volume":"66","author":"Papapoulos SE","year":"2007","unstructured":"Papapoulos SE, Schimmer RC: Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann. Rheum. Dis. 66, 853\u2013858 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_35_2","unstructured":"With intermittent bisphosphonate dosing residual bone turnover marker levels during interdose periods appear more relevant to efficacy than short-term fluctuations.."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.01.008"},{"key":"e_1_3_2_37_2","unstructured":"The large Intravenous Fracture Prevention Study of low-dose quarterly i.v. ibandronate regimens was a first step toward the development of the currently approved i.v. regimen.."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.01.007"},{"key":"e_1_3_2_39_2","unstructured":"The Intermittent Regimen Intravenous Ibandronate Study provided further preliminary findings that informed regimen selection for the Dosing Intravenous Administration (DIVA) study.."},{"key":"e_1_3_2_40_2","unstructured":"Eisman JA Civitelli R Adami S : Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J. Rheumatol. (2008) (Epub ahead of print)."},{"key":"e_1_3_2_41_2","unstructured":"Final results of the DIVA study supporting approval of quarterly i.v. ibandronate.."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325"},{"key":"e_1_3_2_43_2","unstructured":"The BONE study was the first study to establish direct antifracture efficacy with any nondaily bisphosphonate regimen.."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003566"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1402.052"},{"key":"e_1_3_2_46_2","unstructured":"Clinical relevance of annual cumulative exposure and its potential application to development of other new drugs with extended dosing intervals.."},{"key":"e_1_3_2_47_2","first-page":"S210","article-title":"A meta-analysis of individual patient data: significant reduction in non-vertebral fractures with high- versus low-dose ibandronate","volume":"22","author":"Adachi J","year":"2007","unstructured":"Adachi J, Wells G, Papapoulos S, Cranney A, SCIENCE Meta-Analysis Group: A meta-analysis of individual patient data: significant reduction in non-vertebral fractures with high- versus low-dose ibandronate. J. Bone Miner. Res. 22(Suppl. 1), S210 (2007) (Abstract M428).","journal-title":"J. Bone Miner. Res."},{"key":"e_1_3_2_48_2","unstructured":"Meta-analysis demonstrating greater efficacy of i.v. ibandronate compared with all lower-dose ibandronate regimens against fracture at six important nonvertebral sites.."},{"key":"e_1_3_2_49_2","first-page":"681","article-title":"Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data","volume":"66","author":"Cranney A","year":"2007","unstructured":"Cranney A, Wells G, Adachi J: Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data. Ann. Rheum. Dis. 66, 681 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_50_2","first-page":"S451","article-title":"Clinical and nonvertebral fracture risk is reduced with the use of ibandronate in women with postmenopausal osteoporosis","volume":"22","author":"Miller PD","year":"2007","unstructured":"Miller PD, Harris ST, Blumentals WA: Clinical and nonvertebral fracture risk is reduced with the use of ibandronate in women with postmenopausal osteoporosis. J. Bone Miner. Res. 22(Suppl. 1), S451 (2007) (Abstract W355).","journal-title":"J. Bone Miner. Res."},{"key":"e_1_3_2_51_2","unstructured":"Lewiecki EM Babbitt AM Piziak VK Ozturk Z Bone HG: Adherence and gastrointestinal tolerability to oral and intravenous ibandronate in patients with prior gastrointestinal intolerance to oral bisphosphonates. Clin. Therap. (2008) (In Press)."},{"key":"e_1_3_2_52_2","unstructured":"The PRIOR study demonstrated improved tolerance and adherence with quarterly i.v. or monthly oral ibandronate among patients who had discontinued previous oral bisphosphonates as a result of gastrointestinal intolerance.."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"e_1_3_2_54_2","volume-title":"Early communication of an ongoing safety review. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D\u00ae), etidronate (Didronel\u00ae), ibandronate (Boniva\u00ae), pamidronate (Aredia\u00ae), risedronate (Actonel, Actonel w\/Calcium\u00ae), tiludronate (Skelid\u00ae) and zoledronic acid (Reclast, Zometa\u00ae)","author":"Food and Drug Administration","year":"2007","unstructured":"Food and Drug Administration: Early communication of an ongoing safety review. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D\u00ae), etidronate (Didronel\u00ae), ibandronate (Boniva\u00ae), pamidronate (Aredia\u00ae), risedronate (Actonel, Actonel w\/Calcium\u00ae), tiludronate (Skelid\u00ae) and zoledronic acid (Reclast, Zometa\u00ae). 1 October, 2007, US FDA Rockville, MD, USA (2007)."},{"key":"e_1_3_2_55_2","volume-title":"Information for healthcare professionals. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D\u00ae), etidronate (Didronel\u00ae), ibandronate (Boniva\u00ae), pamidronate (Aredia\u00ae), risedronate (Actonel, Actonel w\/Calcium\u00ae), tiludronate (Skelid\u00ae) and zoledronic acid (Reclast, Zometa\u00ae)","author":"Food and Drug Administration","year":"2008","unstructured":"Food and Drug Administration: Information for healthcare professionals. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D\u00ae), etidronate (Didronel\u00ae), ibandronate (Boniva\u00ae), pamidronate (Aredia\u00ae), risedronate (Actonel, Actonel w\/Calcium\u00ae), tiludronate (Skelid\u00ae) and zoledronic acid (Reclast, Zometa\u00ae). 7 January, 2008, US FDA Rockville, MD, USA (2008)."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.11.075"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0422-6"},{"key":"e_1_3_2_58_2","first-page":"174","article-title":"Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs","volume":"7","author":"Schacht E","year":"2007","unstructured":"Schacht E, Dukas L, Richy F: Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J. Musculoskelet. Neuronal Interact. 7, 174\u2013184 (2007).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0190"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050336"},{"key":"e_1_3_2_62_2","unstructured":"Demonstrates efficacy of a sequential regimen following a course of parathyroid hormone with a bisphosphonate.."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1636-z"},{"key":"e_1_3_2_64_2","unstructured":"Demonstrates efficacy of a sequential regimen following teriparatide with a bisphosphonate.."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.10.969"},{"key":"e_1_3_2_66_2","unstructured":"Demonstrates efficacy of an investigational low-dose quarterly i.v. ibandronate regimen to prevent osteoporosis.."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459"},{"key":"e_1_3_2_68_2","unstructured":"Phase II study of denosumab an anti-RANKL monoclonal antibody with antiresorptive activity.."},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061002"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705092200"},{"key":"e_1_3_2_71_2","unstructured":"Modulation of sclerostin expression allows osteocytes to mediate bone formation responses to mechanical stressors.."},{"key":"e_1_3_2_72_2","first-page":"S44","article-title":"Sclerostin monoclonal antibody increases bone strength in aged osteopenic ovariectomized rats","volume":"21","author":"Ominsky MS","year":"2006","unstructured":"Ominsky MS, Asuncion FJ, Tan HL, : Sclerostin monoclonal antibody increases bone strength in aged osteopenic ovariectomized rats. J. Bone Miner. Res. 21(Suppl. 1), S44 (2006) (Abstract 1161).","journal-title":"J. Bone Miner. Res."},{"key":"e_1_3_2_73_2","first-page":"S44","article-title":"Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength","volume":"21","author":"Ominsky MS","year":"2006","unstructured":"Ominsky MS, Stouch B, Doellgast G, : Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. J. Bone Miner. Res. 21(Suppl. 1), S44 (2006) (Abstract 1162).","journal-title":"J. Bone Miner. Res."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0543-5"},{"key":"e_1_3_2_75_2","unstructured":"The WHO's new model incorporates bone mineral density along with bone mineral density-independent factors to predict individuals' absolute fracture risk.."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0559-5"},{"key":"e_1_3_2_77_2","unstructured":"American applications of the FRAX\u2122 model.."}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.4.3.219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.4.3.219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.4.3.219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:13:18Z","timestamp":1767633198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.4.3.219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.2217\/17455057.4.3.219"],"URL":"https:\/\/doi.org\/10.2217\/17455057.4.3.219","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}